262 related articles for article (PubMed ID: 21975331)
1. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer.
Koukourakis GV; Sotiropoulou-Lontou A
Clin Transl Oncol; 2011 Oct; 13(10):710-4. PubMed ID: 21975331
[TBL] [Abstract][Full Text] [Related]
2. Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question.
Koukourakis GV
Recent Pat Inflamm Allergy Drug Discov; 2012 Jan; 6(1):70-7. PubMed ID: 22022926
[TBL] [Abstract][Full Text] [Related]
3. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.
Pavlidis ET; Pavlidis TE
World J Gastroenterol; 2013 Aug; 19(31):5051-60. PubMed ID: 23964138
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab.
Ellis LM
Nat Rev Drug Discov; 2005 May; Suppl():S8-9. PubMed ID: 15962523
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
6. Use of bevacizumab in the treatment of metastatic colorectal cancer.
Raouf S; Bridgewater J; Ellis R; Ferry D; Hill M; Wasan H
Br J Hosp Med (Lond); 2012 Jan; 73(1):25-30. PubMed ID: 22241406
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer.
Lyseng-Williamson KA; Robinson DM
BioDrugs; 2006; 20(3):193-5. PubMed ID: 16724868
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
Fernando NH; Hurwitz HI
Oncologist; 2004; 9 Suppl 1():11-8. PubMed ID: 15178811
[TBL] [Abstract][Full Text] [Related]
9. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in the treatment of colorectal cancer.
Cilley JC; Barfi K; Benson AB; Mulcahy MF
Expert Opin Biol Ther; 2007 May; 7(5):739-49. PubMed ID: 17477810
[TBL] [Abstract][Full Text] [Related]
11. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
Fakih M
Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
14. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
[TBL] [Abstract][Full Text] [Related]
15. Vascular biology support for the use of bevacizumab in colorectal cancer.
Doggrell SA
Expert Opin Investig Drugs; 2004 Jun; 13(6):703-5. PubMed ID: 15174956
[TBL] [Abstract][Full Text] [Related]
16. Managing patients with metastatic colorectal cancer on bevacizumab.
Lemmens L; Claes V; Uzzell M
Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
[TBL] [Abstract][Full Text] [Related]
17. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
18. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in the treatment of colorectal cancer.
Mulcahy MF; Benson AB
Expert Opin Biol Ther; 2005 Jul; 5(7):997-1005. PubMed ID: 16018743
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]